MDxHealth Says Well-Positioned to 'Return to Positive EBITDA'

MDxHealth (NASDAQ:MDXH) reported a second-quarter loss of 18 cents, missing the consensus loss of 16 cents. Sales rose 16% year over year to $27.20 million, beating the consensus of $25.884 million. Tissue-based (Confirm mdx and GPS mdx) test volume was 12,525, a decrease of 1% over the prior-year period, but a 13% sequential increase. Liquid-based (Exo mdx) test volume of 13,578 compared to Select mdx volume of 4,455 for the same period last year. GPS PROMPT Results, AI Initiatives Support Growth. As previously announced in the first-quarter update, the company made the strategic decision to discontinue the Resolve UTI offering to renew our focus on our core prostate cancer business. The company completed this wind-down in Q2, with the permanent cessation of operations.